Skip to main content

REVIEW article

Front. Endocrinol.
Sec. Cancer Endocrinology
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1489767
This article is part of the Research Topic Cancer Biology, Immunotherapy and Aging View all articles

Targeting the FSH/FSHR axis in Ovarian Cancer: Advanced Treatment using Nanotechnology and Immunotherapy The Biological Function of FSH and Nanotechnology and Immunotherapy for the Treatment of Ovarian Cancer Targeting FSHR

Provisionally accepted
Fuqing Feng Fuqing Feng Tianhang Liu Tianhang Liu Xiaoman Hou Xiaoman Hou *Xueyan Lin Xueyan Lin *Yongjie Tian Yongjie Tian *Susu Zhou Susu Zhou *Xiaoyi Qi Xiaoyi Qi *
  • Shandong Provincial Hospital, Jinan, China

The final, formatted version of the article will be published soon.

    Ovarian cancer (OC) is the gynecological malignancy with the poorest prognosis. Surgery and chemotherapy are the primary therapies for OC; however, patients often experience recurrence. Given the intimate interaction between OC cells and the tumor microenvironment (TME), it is imperative to devise treatments that target both tumor cells and TME components. Recently, folliclestimulating hormone (FSH) levels in the blood have been shown to correlate with poorer prognosis in individuals with OC. Ovarian carcinoma cells express FSH receptors (FSHRs). Thus, FSH is an important target in the development of novel therapeutic agents. Here, we review the effects of FSH on normal physiology, including the reproductive, skeletal, cardiac, and fat metabolic systems. Importantly, this review outlines the role and mechanism of the FSH/FSHR axis in the proliferation, survival, and metastasis of OC, providing theoretical support for the targeted FSHR treatment of OC. Current progress in targeting FSHR for OC, including the recent application of nanotechnology and immunotherapy, is presented. Finally, we discuss prospects and future directions of targeted FSHR therapy in OC. 1 Introduction Ovarian cancer (OC) is the seventh most prevalent cancer in women worldwide, and the most lethal

    Keywords: FSHR, ovarian cancer, targeted therapy, Nanotechnology, Immunotherapy

    Received: 01 Sep 2024; Accepted: 02 Dec 2024.

    Copyright: © 2024 Feng, Liu, Hou, Lin, Tian, Zhou and Qi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xiaoman Hou, Shandong Provincial Hospital, Jinan, China
    Xueyan Lin, Shandong Provincial Hospital, Jinan, China
    Yongjie Tian, Shandong Provincial Hospital, Jinan, China
    Susu Zhou, Shandong Provincial Hospital, Jinan, China
    Xiaoyi Qi, Shandong Provincial Hospital, Jinan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.